| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
InspireMD Inc (NASDAQ: NSPR)
NSPR Technical Analysis
4
| As on 9th Jun 2023 NSPR STOCK Price closed @ 1.69 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.17 & Strong Sell for SHORT-TERM with Stoploss of 2.80 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NSPRSTOCK Price
| Open | 1.73 | Change | Price | % |
| High | 1.73 | 1 Day | -0.02 | -1.17 |
| Low | 1.68 | 1 Week | 0.07 | 4.32 |
| Close | 1.69 | 1 Month | 0.63 | 59.43 |
| Volume | 12400 | 1 Year | -1.62 | -48.94 |
| 52 Week High 3.39 | 52 Week Low 0.81 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NSPR Daily Charts |
NSPR Intraday Charts |
Whats New @ Bazaartrend |
NSPR Free Analysis |
|
|
NSPR Important Levels Intraday
| RESISTANCE | 1.79 |
| RESISTANCE | 1.76 |
| RESISTANCE | 1.74 |
| RESISTANCE | 1.72 |
| SUPPORT | 1.66 |
| SUPPORT | 1.64 |
| SUPPORT | 1.62 |
| SUPPORT | 1.59 |
NSPR Forecast May 2024
| 4th UP Forecast | 3.17 |
| 3rd UP Forecast | 2.7 |
| 2nd UP Forecast | 2.4 |
| 1st UP Forecast | 2.11 |
| 1st DOWN Forecast | 1.27 |
| 2nd DOWN Forecast | 0.98 |
| 3rd DOWN Forecast | 0.68 |
| 4th DOWN Forecast | 0.21 |
NSPR Weekly Forecast
| 4th UP Forecast | 2.60 |
| 3rd UP Forecast | 2.31 |
| 2nd UP Forecast | 2.13 |
| 1st UP Forecast | 1.95 |
| 1st DOWN Forecast | 1.43 |
| 2nd DOWN Forecast | 1.25 |
| 3rd DOWN Forecast | 1.07 |
| 4th DOWN Forecast | 0.78 |
NSPR Forecast2024
| 4th UP Forecast | 6.74 |
| 3rd UP Forecast | 5.12 |
| 2nd UP Forecast | 4.12 |
| 1st UP Forecast | 3.12 |
| 1st DOWN Forecast | 0.26 |
| 2nd DOWN Forecast | -0.74 |
| 3rd DOWN Forecast | -1.74 |
| 4th DOWN Forecast | -3.36 |
InspireMD Inc ( NASDAQ USA Symbol : NSPR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NSPR Business Profile
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel. Address: 4 Menorat Hamaor Street, Tel Aviv, Israel, 6744832
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service